There has been an increased use of commercial kits for biomarker measurement, commensurate with the increased demand for biomarkers in drug development. However, in most cases these kits do not meet the quality attributes for use in regulated environment. The process for adaptation of these kits can be frustrating, time consuming and resource intensive. In addition, a lack of harmonized guidance for the validation of biomarker poses a significant challenge in the adaptation of kits in a regulated environment. The purpose of this perspective is to propose a tiered approach to commercial drug development kits with clearly defined quality attributes and to demonstrate how these kits can be adapted to perform analytical validation in a regulated environment.
concerns for the use of RUO kits are lot to lot variability, reagent stability, the lack of appropriate quality controls (QCs) and the calibrator used may not be traceable to a reference standard. In many cases, the user will need to optimize the assay for the intended use, including adding calibrator points, matrix QCs, reagent substitution and curve fitting. Additionally, the assay will need to have its sensitivity and stability determined. Many times a kit will have a defined LOD versus an LOQ which is a desired parameter. However, they serve as very useful tools in the drug development process, as in many cases they are the first to market for novel biomarkers and the assays can be more adaptable and optimized as a drug development tool [3] .
In vitro diagnostic (IVD) kits come in several classes (Class I, II or III). As these kits are considered medical devices, they are classified according to the level of complexity and risk. All must undergo FDA review and approval through premarketing approval and the 510(k) process. The quality requirements for these kits are specified in 21 Code of Federal Regulations (CFR) 522. While the development and assay performance are clearly characterized, these kits may not have the required range or sensitivity required. Many of these kits are 'closed' systems, where substituting reagents or modifying assay parameters are not possible. As outlined in the 2013 Draft FDA guidelines, these kits must be adapted to be shown suitable for drug development studies [4] . They often consist of one-or two-point calibration curves and must be validated with at least six calibration points. The number of QCs provided in IVD kits, in most cases, are not sufficient and additional QCs need to be added. Also, the acceptance criteria based on concentration range need to be substituted with percent bias from nominal concentration.
Clinical Laboratory Improvement Amendments (CLIA) tests are designed specifically for diagnostic purposes and follow quality standards as defined by the Clinical and Laboratory Standards Institute (CLSI). These assays fall into three different categories based on the complexity of their execution: waved, moderate and high. These kits may not have sufficient assay performance characteristics beyond their approved use.
Conformité Européenne (CE)-marked kits are for products marketed in the European Economic Area. While the CE mark implies conformity to safety and manufacturing requirements established by the EU, the process is mostly self directed. There are some categories of devices that will require a third-party review. While the CE mark denotes a certain standard for manufacturing, it does not guarantee that the assay is suitable for the measurement of biomarkers. As with the other types of kits, they may need to be optimized for its context of use.
Challenges in the adaptation of biomarker kits
Commercial kits are appealing to bioanalytical scientists due to their immediate availability and perceived quality. Using commercially available kits have a potential for time and cost savings by eliminating the need for developing reagents and assays 'from scratch'. However, due to the high variability in quality, it is difficult to assess the assay performance before purchase. As a result, in most cases the desired assay quality is not achieved in a cost-effective manner. In order to have an assay appropriate for the context of use, assay optimization, and in some cases assay reconstruction, are required.
Most commercial kits are developed for diagnostic purposes or drug discovery purposes, as opposed to drug development. There is an unmet need for 'well-defined' commercial kits that can be utilized in a drug development setting. While the quality of the FDA-approved IVD kits are manufactured using stringent quality systems, as illustrated by the case study below, they fail to meet drug development objectives. All commercial kits, excluding IVD kits, are marked as RUO. As previously mentioned, RUO kits do not have any harmonized quality standards and their performance characteristics vary significantly.
For example, in a recent paper evaluating commercial biomarker kits for a cardiac biomarker (human tyrosineprotein phosphatase nonreceptor type substrate 1 α [SIRPA]), the authors presented data that indicate the variability in the quality and utility of these kits [5] . Two ELISA kits for the quantitation of SIRPA were evaluated by running samples using both kits. To verify the identity of the protein being detected, the calibrators included in the kits were evaluated by western blot and MS, using a recombinant human SIRPA as a control. The results of the western blot indicated that neither kit calibrator reacted with an anti-SIRPA antibody. The results of the MS analysis showed no SIRPA being detected in either kit calibrator. While the kits generated results that corresponded with the expected values for the samples, further reagent characterization showed that the kit was not detecting the intended target. This demonstrates that the lack of analytical validation and insufficient reagent characterization are common issues with biomarker kits.
Multiplexed commercial kits that evaluate many related analytes in one assay are also becoming more common. A detailed discussion of the challenges and solutions in using multiplexed biomarker kits for drug development has been highlighted previously and is outside the scope of this discussion [6, 7] . However, a recent study by Fischer et al. highlights the significant challenges of using multiplex kits for drug development [7] . Only 18 out of 47 assays in multiplexed kits met the set bioanalytical acceptance criteria and assay sensitivity significantly diminished when using study matrix. This is another example of poor assay performance characteristics found in biomarker kits.
Some vendors have attempted to stratify the quality of their kits by using their own trademark names such as the V-Plex line of kits from Meso Scale Discovery, pharmacokinetic (PK) or anti-drug antibody (ADA) kits from Somru BioScience and Quantikine kits from R&D systems. However, the definitions of these kits and their contents are ambiguous and inconsistent from vendor to vendor.
With an increased interest in the use of biomarkers in drug development, not surprisingly, the regulatory scrutiny on the analytical validity of the biomarkers has increased. This is evidenced by the most recent FDA bioanalytical guidance document (2013) which requires stringent analytical validation requirements for biomarkers used for regulatory decision making [4, 8] . Faced with an increased demand for biomarker assays and the high regulatory scrutiny, bioanalytical scientists are scrambling to develop and validate assays in quality manner, in most cases using commercial kits.
In order to overcome these challenges, we propose two solutions that will greatly alleviate this situation. First, we propose the term of drug development kits (DDK) with tiered and defined quality attributes. Second, we provide a framework to organize different regulatory and industry recommendations for the analytical validation of biomarkers to streamline the adaptation of commercial kits.
A context of use of framework for commercial kit adaptation Detailed guidelines for the adaptation of commercial kits for biomarker bioanalytical assays have been published several times over the last decade [3, 4, [8] [9] [10] [11] . For example, Khan et al. provides a detailed workflow of creating a biomarker work plan (BWP) to determine the fit for purpose level of validation necessary for the assay, performing a feasibility comparison of kits, and finally validating the chosen kit with necessary adaptations. These guidelines provide the most comprehensive and valid approach to adaptation of a biomarker kit to date. However, recent publications recommend using guidelines developed by the FDA and CLSI for other aspects of biomarkers used in clinical studies for their use in bioanalytical assays [12] . The recommendations in this paper focus on using the principle of fit-for-purpose context of use (COU) for adapting commercial kits for bioanalytical methods.
The FDA Biomarker Qualification Program is a mechanism to qualify and use biomarkers for use in clinical studies. Each biomarker allowed for use in a study should have a specific COU, which is 'a statement that fully and clearly describes the way the medical product tool is to be used and the medical product developmentrelated purpose of use' [13] . The COU of the biomarker in drug development should be established early in assay development. The COU should be specific to the disease or condition being studied, and may include screening for a drug target, assessment of risk, assessment of prognostic outcome, or asses a toxic or safety concern.
For bioanalytical biomarker assays, the level of validation must be sufficient to support the biomarker's COU [13] . For commercial kits, determination of the adaptations necessary for a kit thus starts with a BWP that defines the COU (Table 1 ). This BWP helps guide decisions in validation as parameters such as sensitivity, precision, study matrix and determination of matrix effects must fit the COU and the disease being studied.
Recent approaches for biomarker validation have also defined three tiers of validation to better fit and provide more flexibility for the different uses of biomarkers during drug development to supplement the traditional two tiers of method qualification and validation [3, 12] . Shown in Table 2 , these tiers are defined with their recommended test parameters for exploratory validation (Tier I), partial validation (Tier II) and full validation (Tier III). The tier of validation is dependent primarily on whether the COU involves submission to a regulatory body for decision making or is used for internal decision making. Early in the drug development process where biomarkers are used for internal decisions of screening, determination of the drug's mechanism of action and optimization of a drug, a tier I or II validation is recommended to obtain rapid yet reliable information. Later in the process, where decisions of patient safety and drug efficacy are made by a regulatory body, a full tier III validation in accordance with FDA bioanalytical guidelines must be performed regardless of whether the study is clinical or nonclinical. The addition of a middle tier (tier II) allows for greater flexibility in designing assays that fall in a gray area between discovery and regulatory labels while allowing easier validation of an assay up to tier III if the COU is changed.
It is important to note that the validation of the kit is specific to the COU and the disease being studied. Changes to the COU may change the validation tier and thus a new BWP must be drafted to evaluate if new modifications are needed to the assay and kit. This validation workflow provides an updated framework for adapting commercial biomarker kits, which are in accordance with how the biomarker is being used.
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Parameter Analyte(s) Creatinine
Context of use (e.g., disease sample screening, lead biomarker screening, target optimization, assessment of susceptibility, assessment of prognostic outcome, assessment of toxicity)
Determination of urine creatinine for calculation and normalization of biomarkers in human urine after dosing of tobacco products (regulatory submission) Summary of validation level and kit adaptations Tier III full bioanalytical method validation of the silver DDK enzymatic creatinine kit:
• 6 STDs prepared and 3 endogenous QCs in human urine.
• Calibrator from NIST creatinine standard.
• Matrix effect testing in urine instead of serum to determine MRD Use of multiplexed biomarker kits, while more complex, requires the same framework of forming a BWP with COU statement for determining which tier of validation is necessary for the kit. It is recommended that the number of analytes measured in a single assay be evaluated against the COU. While there is not yet consensus on the exact number, a large number of analytes in a single assay should not be used for regulatory submissions. Late-stage trials are expected to use singleplex assays [6] .
Utility of CLSI & FDA guidelines for biomarkers
Another recommendation from recent guidelines is to utilize guidelines from CLSI and CLIA, which have been measuring biomarkers for over 40 years in the clinical and diagnostic laboratory environment [6, 12, 14] .
The push to harmonize CLSI diagnostic assay guidelines for biomarkers with FDA bioanalytical drug development assay guidelines can be applied to the adaptation of commercial kits. In order to harmonize these guidelines, a comparison should be made of the validation requirements for both methodologies and the pros and cons of both approaches [15] . Both the FDA bioanalytical guidance and the CLSI biomarker guidelines have similar detailed reporting, training and record-keeping requirements, as well as a quality system dedicated to ensuring traceable and quality results, and so are very similar in the spirit of the content. However, the goals of CLSI assays and FDA bioanalytical assays are largely separate. CLSI assays are validated to distinguish healthy from diseased individuals, while bioanalytical assays are used to quantitate changes for the determination of drug efficacy and safety [9] . For example, while reference ranges are necessary for clinical diagnostic purposes, reference ranges do not have the same use in drug development studies.
It is important to note that efforts to harmonize CLSI and FDA guidelines refer to the entire process of validation for all biomarker assays. However, some general principles discussed below can be applied to adapting a biomarker kit in method development and validation. Which guidelines should be used are dependent on the tier of biomarker validation. In particular, three CLSI guidelines for immunoassays are well applied to the adaptation of kits for drug development:
• Reference standard traceability: CLSI guidelines for immunoassays stipulate that assays should use traceable national or international standards for reference materials to establish accuracy of assays [16] . Since immunoassays commonly do not have developed such standards, when such material is unavailable, manufacturers should establish in-house measurement standards to support and document the assignment of values for calibrators. These recommendations are highly applicable to the development and validation of kits for drug development.
Tier III biomarker validations should use WHO, National Institute for Biological Standards or National Institute for Standards and Technology reference material when available. When unavailable, assignment of reference values should be documented through characterization of purity, potency and concentration of the material by the end user and/or vendor.
• Interference tests: CLSI assays for biomarkers undergo extensive tests for interference for determination of linearity, specificity and matrix effects [17] [18] [19] . Use of patient samples and disease matrix to determine matrix effect, fortification of samples with hemoglobin or lipids, and comparison of different anticoagulants used for sample collection are all specified. These tests add valuable information for endogenous biomarkers that may be modified or are subject to interfering compounds during disease processes. Accordingly, our recommendations for the determination of matrix effect and QCs include the use of matrix from the disease specified in the COU in certain validation tiers (Table 2 ).
• Definition of measurement ranges: the definition and reporting for sensitivity and quantifiable range often differ from vendor to vendor for RUO kits especially in cases when a minimum required dilution is present. CLSI guidelines for IVD kits require definition of a measurement range and a reportable range [16] . The reportable range of samples may exceed the analytical measurement range when dilutions are used. For drug development kits and validation reports, the LLOQ and ULOQ should be consistently defined accounting for dilutions of samples.
Time is right for drug development kits
In most cases neither RUO) kits nor diagnostics IVD kits meet the quality attributes required for drug development. Bioanalytical scientists are left with commercial kits with 'black box' quality attributes to validate biomarker methods. The process can be frustrating, time consuming and resource intensive. Ultimately, the desired efficiency and/or productivity gains, potentially could be attained by utilizing a commercial kit, are lost.
future science group www.future-science.com In our opinion, given the rapid growth in biomarker analysis in the drug development environment, this impasse faced by bioanalytical scientists can be a significant opportunity for kit manufacturers. There is a sufficient demand today for kit manufacturers to consider creating purpose-built DDK. We also feel that the bioanalytical community is eager to collaborate with the kit manufacturers to improve this situation. This can be a win-win proposition for the bioanalytical community and the kit manufacturers. There have been calls in the past from the industry for kits developed specifically for drug development in the same vein as kits developed specifically for diagnostics (e.g., pharmaceutical grade) [20] . However, we believe the framework and recommendations for kit contents and assay performance presented here set the foundation for these kits for discussion of the practical considerations at future meetings. This will enable delivery of quality data that will meet increased regulatory scrutiny and ultimately help bring effective and safe drugs to market to benefit patients.
A tiered framework for drug development kits
After the evaluation of currently available kits, we identified the following three key areas of deficiencies of commercial kits:
• Critical reagents including reference materials characterization;
• Verification of assay performance characteristics; and • Documentation.
This framework for DDKs with tiered essential quality attributes is consistent with the three-tiered validation approach presented in Table 2 and the most recent industry guidelines for biomarkers. For simplicity, we decided to present the tiers as universally understood 'metal' categories: gold, silver and bronze. An example of use of these different categories is presented in Table 3 . These recommendations are intended to be the minimal criteria for harmonizing critical reagents characterization, method performance and necessary documentation to enable their seamless transition and adaptation in a regulatory-compliant bioanalytical lab. Gold DDKs require kits with an international or national reference material which are applicable to a limited amount of analytes. However, this does not preclude the use of kits without international reference standards from being used for full tier III validation for regulatory work. As demonstrated in Figure 1 , it is the responsibility of the bioanalytical laboratory to validate the kit chosen to the appropriate tier. Critical reagents are the essential components of ligand binding methods. In the context of kit-based assays they include reference material/calibrator, coating antibody and detection antibody. Unlike LC-MS, these methods require specific and unique biomolecular interactions between the critical reagents and the reference analyte [21] . The characteristics of these critical reagents can have a significant impact on assay reliability and reproducibility; therefore, the reagents require thorough characterization and documentation. We recommend following the tiered characterization approach taking into account not only scientific needs but also resource needs and cost implications (Table 4) .
Assay performance characteristics for commercial RUO kits vary significantly from vendor to vendor and in most cases even from kit to kit within the same vendor. In the case of IVD kits, (premarket approval or 510 K) the performance characteristics are well defined. However, they are often defined for diagnostic applications with limited pathological conditions and are, in most cases, designed for closed instrument systems. This necessitates the need for well-defined performance characteristics for drug development kits that will enable bioanalytical scientists to choose the right kit for the right job. A recommendation on performance characteristics for DDKs is included in Table 3 .
As with performance characteristics, the documentation included with the kits are highly variable and often lack critical documentation such as reference material characterization data, assay performance data, assay acceptance criteria and kit release criteria. This framework ensures consistency in documentation for DDKs. For gold and silver kits, documentation should include a certificate of analysis for the reference material, critical reagents and QCs. Kit performance data outlining experimental parameters, results and lot to lot bridging should also be included to assist end users during assay feasibility, gap analysis and validation.
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Case study: development of a DDK & its subsequent validation
Creatinine is a diagnostic assay most commonly measured in human serum for the assessment of kidney function. However, the correction of urine biomarker measurements using urine creatinine concentration is a widely used application of creatinine in drug development. Most assays for the measurement of creatinine are run using an IVD kit to distinguish diseased patients from healthy patients. These kits do not have the appropriate assay design (e.g., number of standards and QC samples, etc.) that is required to meet FDA BMV guidance necessitating kit modifications.
Using the workflow outlined in Figure 1 and Table 5 , we first developed a BWP with a COU statement and determined a tier III full validation was necessary since the data generated from the assay are used for regulatory decision making (Table 1) . We collaborated to develop a DDK kit (silver grade) and then adapted the kit to perform a tier III validation. Kit development work was performed by Somru Bioscience, Inc. and regulatory compliant validation work was performed by Celerion, Inc.
The reference material was characterized for MW, purity, potency and concentration. The parallelism test was performed using National Institute of Standard's reference material SRM 3667. The assay was revised to have six nonzero calibration points, and the calibration curve range took into account the target range in smoker population. Accuracy and precision of the assay were demonstrated by running QC. Two of the QC samples were prepared in urine. Additional QC samples were prepared by diluting urine samples using assay buffer. Specificity was evaluated by the fortification of creatinine, hemoglobin and ascorbic acid into QC samples. All the critical reagents were characterized and lot to lot consistency was verified.
Additional adaptations were done at the bioanalytical lab to complete a tier III validation for the specific context of use. The calibrator was switched to use National Institute for Standards and Technology SRM 3667 for better traceability. The validation also adapted the matrix effect testing and the QC samples into the intended matrix of human urine from smoker's population. Endogenous QC samples were made by screening and subsequent pooling of urine lots at appropriate concentration. Since low endogenous levels were not available, human urine was diluted in assay buffer to create low QC samples. The ULOQ QC was generated by spiking endogenous QC samples with kit calibrator. Accuracy, precision and matrix effect evaluation was performed as per FDA Bioanalytical Method Validation guideline. Finally, short term, freeze-thaw and long-term stability was evaluated using QC samples prepared using endogenous QC samples. The FDA compliant validation demonstrated the appropriateness of the use of the study matrix, showing an acceptable recovery of creatinine during accuracy and precision. No significant matrix effect was observed in any of the ten human urine lots that were fortified at 618 μg/ml after a minimum required dilution of four. Three QC samples in human urine and ULOQ and LLOQ QC samples in assay buffer across the entire range of the assay were utilized for determining accuracy and precision. Accuracy was shown to range from -4.3 to 0% bias, and precision was shown to range from 3.9 to 5.6%. The LLOQ and ULOQ was reliably shown to be 30 and 600 μg/ml (measurement range) with a reportable range of 120 to 2400 μg/ml. Both long-term and short-term stabilities, bracketing the time period between samples collection and sample analysis, were demonstrated. In addition, incurred sample reanalysis, as required by FDA guidelines, was performed on various studies and results were reproducible for >90% of samples.
This case study illustrates the importance for collaboration between kit manufacturers and the bioanalytical laboratory to achieve successful regulatory compliant assay validation that is appropriate for the COU.
Conclusion
In this article, we present a tiered framework for biomarker commercial kits and their validation based on a biomarker's COU to serve as a starting point for a call for action. The case study of a creatinine DDK by the vendor and subsequent tier III validation by the validating lab presented above demonstrates the feasibility of this approach. However, harmonization and finalization of details (e.g., terminology, specific validation tests for each tier) will require repeated discussions between industry partners and regulatory agencies at future meetings. It is the hope of the authors that this article will help stimulate the discussions necessary among all relevant parties to remove the barriers and to establish a standardized process for the development and adaptation of commercial kits.
Future perspective
Today, and in the next era of drug development, we expect increased use of biomarkers in drug development to expedite scientific and regulatory decision making. Since biomarkers can predict drug pharmacological mechanism, future science group www.future-science.com efficacy and safety more quickly than conventional clinical end points, they hold the potential to reduce drug development costs and substantially reduce the product development timeline. In fact, in some estimates just a 10% improvement in the ability to predict drug failures before clinical trials could save US$100 million in development costs per drug [24] . However, there are two major hurdles we need to overcome in order to reap the benefit of biomarkers. First, we need to overcome the lack of a standardized approach to the validation of biomarkers that take into account technological innovation, and context of use under harmonized regulatory guidelines. In this article, we provide a framework for validation of biomarkers and biomarker kits that take into account the most recent FDA Bioanalytical guidelines, various recent discussions between industry partners and regulatory authorities, and applicable CLSI guidelines.
Second is the lack of standardization for reagents and assay quality attributes for commercial kits. We present a recommendation for the development of 'drug development kits' with standardized quality attributes. We believe an initial investment by manufacturers to design and test three tiers of kits prior to release, similarly tiered characterization of critical reagents and sharing of data through documentation provides feasible steps to increase the utility of commercial kits. A well-defined biomarker kit standardization strategy can be a way for a company to differentiate its product and itself in a highly competitive commercial kit market. Due to intense regulatory demand for quality biomarker data, we believe that in the coming decades, in order for a kit manufacturer to have a significant impact in this market, it will be essential to improve kit quality and implement some form of standardization. It is possible that if kit manufacturers do not make these changes, they put themselves at risk of becoming irrelevant or becoming obsolete. Ultimately, overcoming these hurdles will bring the benefit of biomarkers to patients by accelerating cost-effective drug development.
Executive summary

Challenges in adaptation of commercial kits
• There has been increased use of commercial kits for bioanalysis of biomarkers commensurate with the increased demand for biomarkers in regulated drug development settings.
• The adoption of commercial kits has been hindered due to highly variable quality of commercial kits and lack of harmonized guidance on analytical validation of biomarkers.
• Here we propose a framework for analytical validation of biomarkers that harmonizes the recommendation from US FDA and Clinical and Laboratory Standards Institute. We also propose a framework for the development of drug development kits -a new class of kits with defined quality attributes.
Harmonization of FDA & Clinical and Laboratory Standards Institute guidelines
• New recommendations attempt to harmonize bioanalytical, Clinical and Laboratory Standards Institute and FDA bioanalytical guidelines and the FDA Biomarker Qualification Program.
